Alector announces first patient dosed in progress-ad phase 2 clinical trial of al101/gsk4527226 in patients with early alzheimer's disease

The trial, being conducted in partnership with gsk, is expected to enroll approximately 282 patients globally the trial, being conducted in partnership with gsk, is expected to enroll approximately 282 patients globally

ALEC Ratings Summary

ALEC Quant Ranking